Literature DB >> 27917077

The Role of Liver Biopsy in Hepatocellular Carcinoma.

Richard S Finn1.   

Abstract

Entities:  

Year:  2016        PMID： 27917077      PMCID： PMC5114505     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

2.  Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.

Authors:  Eric T Sawey; Maia Chanrion; Chunlin Cai; Guanming Wu; Jianping Zhang; Lars Zender; Alice Zhao; Ronald W Busuttil; Herman Yee; Lincoln Stein; Dorothy M French; Richard S Finn; Scott W Lowe; Scott Powers
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

3.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

4.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
  4 in total
  6 in total

1.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

2.  Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies.

Authors:  David J Tischfield; Daniel Ackerman; Michael Noji; James X Chen; Omar Johnson; Nicholas R Perkons; Gregory J Nadolski; Stephen J Hunt; Michael C Soulen; Emma E Furth; Terence P Gade
Journal:  Sci Rep       Date:  2019-07-22       Impact factor: 4.379

Review 3.  Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma.

Authors:  Natthaphong Nimitrungtawee; Nakarin Inmutto; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cancer Med       Date:  2021-10-28       Impact factor: 4.452

Review 4.  Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review.

Authors:  Santhasiri Orrapin; Sasimol Udomruk; Worakitti Lapisatepun; Sutpirat Moonmuang; Areerak Phanphaisarn; Phichayut Phinyo; Dumnoensun Pruksakorn; Parunya Chaiyawat
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

5.  Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis.

Authors:  Debra T Choi; Jessica A Davila; Shubhada Sansgiry; Eric David; Hardeep Singh; Hashem B El-Serag; Yvonne Hsiao-Fan Sada
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-18       Impact factor: 13.576

6.  Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.

Authors:  Bo Hyun Kim; Joong-Won Park; Jin Sook Kim; Sook-Kyung Lee; Eun Kyung Hong
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.